0001193125-23-144030.txt : 20230515 0001193125-23-144030.hdr.sgml : 20230515 20230515060700 ACCESSION NUMBER: 0001193125-23-144030 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230510 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230515 DATE AS OF CHANGE: 20230515 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCEPT INC CENTRAL INDEX KEY: 0001044378 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 800943522 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-36284 FILM NUMBER: 23918120 BUSINESS ADDRESS: STREET 1: 9955 MESA RIM ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-320-8200 MAIL ADDRESS: STREET 1: 9955 MESA RIM ROAD CITY: SAN DIEGO STATE: CA ZIP: 92121 8-K 1 d420466d8k.htm 8-K 8-K
BIOCEPT INC false 0001044378 0001044378 2023-05-10 2023-05-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 10, 2023

 

 

BIOCEPT, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-36284   80-0943522

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

9955 Mesa Rim Road, San Diego, CA   92121
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (858) 320-8200

N/A

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

   

Trading

Symbol(s)

   

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share    BIOC    The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 2.02

Results of Operations and Financial Condition.

On May 10, 2023, Biocept, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2023. A copy of the press release and accompanying information is attached as Exhibit 99.1 to this current report.

The information in this Item 2.02, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this current report shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

 

Item 3.01

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

As reported in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, as filed with the Securities and Exchange Commission on May 10, 2023, the Company’s stockholders’ equity as of March 31, 2023 was $2.4 million. As a result, the Company does not satisfy one of The Nasdaq Capital Market continued listing requirements set forth in Nasdaq Stock Market Rule 5550(b) (the “Rule”).

The Company expects to receive a formal notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”) on or about May 15, 2023 to formally notify the Company of non-compliance with the Rule. The Company discussed the noncompliance with the Rule with Nasdaq on May 12, 2023.

Pursuant to the Notice and Nasdaq rules, the Company will have 45 calendar days after receipt of the Notice to submit a plan to regain compliance with the Rule. If the plan is accepted, Nasdaq may grant an extension of up to 180 calendar days from the date of the Notice for the Company to provide evidence of compliance. There can be no assurance that the Company will be able to regain compliance with the Rule.

 

Item 5.07

Submission of Matters to a Vote of Security Holders.

On May 11, 2023, the Company held a Special Meeting of Stockholders (the “Special Meeting”). The following is a brief description of each matter voted upon at the Special Meeting, as well as the number of votes with respect to each matter. Voting results are, when applicable, reported by rounding fractional share voting down to the nearest whole number.

Proposal 1. Approval of a Series of Alternate Amendments to our Amended and Restated Certificate of Incorporation to Authorize the Board of Directors to Implement a Reverse Stock Split of our Common Stock

The Company’s stockholders approved a series of alternate amendments to the Company’s Amended and Restated Certificate of Incorporation to effect, at the option of the Company’s Board of Directors (the “Board”), a reverse stock split of the Company’s common stock at a ratio between 1-for-15 and 1-for-30, inclusive as determined by the Board in its sole discretion. The final voting results, including 300,000,000 votes represented by the share of Series B Preferred Stock voted in the same proportion as the votes cast by shares of common stock on Proposal 1, are as follows:

 

Votes For

  

Votes Against

  

Abstentions

  

Broker

Non-Votes

186,084,407

   116,708,364   73,495   0

Proposal 2. Approval of the Authorization to Adjourn the Special Meeting

The Company’s stockholders approved the authorization to adjourn the Special Meeting, if necessary, to solicit additional proxies if there were not sufficient votes in favor of Proposal 1, but this authorization is moot as Proposal 1 passed. The final voting results are as follows:

 

Votes For

  

Votes Against

  

Abstentions

  

Broker

Non-Votes

4,574,843

   2,758,298   95,195   0

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

   

Description

99.1    Press Release dated May 10, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BIOCEPT, INC.
Dated: May 15, 2023   By:  

/s/ Samuel D. Riccitelli

  Name:   Samuel D. Riccitelli
  Title:   Interim President and Chief Executive Officer
 EX-99.1 2 d420466dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Biocept Reports First Quarter 2023 Financial Results

SAN DIEGO (May 10, 2023) – Biocept, Inc. (Nasdaq: BIOC), a leading provider of molecular diagnostic assays, products and services, reports financial results for the three months ended March 31, 2023 and provides a business update.

“I’m exceptionally pleased with the progress being made with our FORESEE clinical trial, which is specifically designed to generate evidence of CNSide™’s clinical utility to support adoption into clinical care guidelines and further broaden physician use. Trial enrollment is running well in line with our plan, and we’ve now activated clinical sites in Dallas, Los Angeles and the San Francisco Bay Area,” said Samuel D. Riccitelli, Biocept’s Chairman, and interim President and CEO. “In our quest to gain further physician and payor acceptance, we submitted an article to a peer-reviewed journal describing our assay, its attributes, and the work to demonstrate CNSide’s performance validity. We expect two additional manuscripts to be submitted for peer-review later this year by leading neuro-oncologists detailing their experience with CNSide through case study reports.

“We have begun requiring all new customers to sign lab service agreements prior to commencing use of our assay to facilitate fair and turnkey reimbursement for CNSide testing, and we are negotiating similar agreements with current customers. Nearly half of our existing clients have engaged with us on this matter and although the program has yielded only two signed agreements to date, we are hopeful this will allow us to continue to offer CNSide in a more cost-effective manner going forward,” he added. “Additionally, our cost-control measures put in place over the past year continued to drive down expenses.

“We look forward to providing a progress report and updates on the FORESEE trial when we resume holding quarterly investor calls with reporting of second quarter financial results in mid-August,” Mr. Riccitelli concluded.

First Quarter Financial Results

Net revenues for the first quarter of 2023 were $0.7 million, compared with $19.9 million for the first quarter of 2022, with the decline due to lower RT-PCR COVID-19 testing volume. In February 2023 the Company ceased providing COVID-19 testing services. The number of commercial accessions delivered for the first quarters of 2023 and 2022 were 3,085 and 153,056, respectively.

Cost of revenues for the first quarter of 2023 was $3.0 million, compared with $10.3 million for the first quarter of 2022, with the decrease primarily associated with the cessation of COVID-19 testing services.

Research and development expenses for the first quarter of 2023 were $1.0 million, compared with $1.8 million for the first quarter of 2022, with the decrease primarily due to a reduction in headcount and lower purchases of materials and supplies.

General and administrative expenses for the first quarter of 2023 were $3.0 million, compared with $6.3 million for the first quarter of 2022. The decrease was primarily due to lower legal and outside service expenses in the 2023 quarter, and separation agreements with former executive management in the 2022 quarter.

Sales and marketing expenses for the first quarter of 2023 were $0.7 million, compared with $3.7 million for the first quarter of 2022, with the decrease primarily due to fewer sales representatives, lower commission expense and a decrease in outside services expenses.

Net loss attributable to common stockholders for the first quarter of 2023 was $7.1 million, or $0.41 per share, compared with a net loss attributable to common stockholders for the first quarter of 2022 of $2.2 million, or $0.13 per share.

Biocept reported cash of $6.8 million as of March 31, 2023, compared with $12.9 million as of December 31, 2022.

About Biocept

Biocept, Inc. develops and commercializes molecular diagnostic assays that provide physicians with clinically actionable information for treating and monitoring patients diagnosed with a variety of cancers. For more information, visit www.biocept.com. Follow Biocept on Facebook, LinkedIn, Twitter, and Instagram.

Forward-Looking Statements Disclaimer Statement

This news release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to be correct. Forward-looking statements are generally identifiable by the use of words like “will,” “expect,” “goal,” “objective,” “believe” or “intend” or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this news release are not strictly historical, including, without limitation, statements regarding FORESEE’s potential to generate evidence of CNSide’s clinical utility to support adoption into clinical care guidelines and further broaden physician use and payor acceptance, our expectation that two additional manuscripts will be submitted for peer-review later this year by leading neuro-oncologists detailing their experience with CNSide, our hope that requiring lab service agreements will allow us to continue to offer CNSide in a more cost-effective manner going forward, future progress reports on the FORESEE trial and the timing thereof, and other statements that are not historical fact, are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risks and uncertainties, including that the results of the FORESEE clinical trial may not support the inclusion of CNSide in clinical care guidelines; Medicare and private payors may not provide coverage and reimbursement or may breach, rescind or modify their contracts or reimbursement policies or delay payments; our customers may choose not to enter into lab service agreements with us; risks related to our need for additional capital; and the risk that our products and services may not perform as expected. These and other factors are described in greater detail under the “Risk Factors” heading in our Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission (SEC) on April 17, 2023, and in our Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, which is being filed with the SEC today. The effects of such risks and uncertainties could cause actual results to differ materially from the forward-looking statements contained in this news release. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law. Readers are advised to review our filings with the SEC at http://www.sec.gov/.

Investor & Media Contact:

LHA Investor Relations    

Jody Cain

Jcain@lhai.com

(310) 691-7100    

 

2

Biocept, Inc.

Condensed Balance Sheets

(In thousands, except share and per share data)

 

     March 31,
2023		     December 31,
2022		  
     (unaudited)        

Assets

     

Current assets:

     

Cash

    $ 6,774     $ 12,897  

Accounts receivable

      1,112       2,151  

Inventories, net

      704       757  

Prepaid expenses and other current assets

      500       538  
  

 

 

    

 

 

  

Total current assets

      9,090       16,343  

Fixed assets, net

      2,513       2,572  

Lease right-of-use asset—operating

      8,339       8,486  

Lease right-of-use assets—finance

      2,665       3,086  

Other non-current assets

      386       386  
  

 

 

    

 

 

  

Total assets

    $ 22,993     $ 30,873  
  

 

 

    

 

 

  

Liabilities and Stockholders’ Equity

     

Current liabilities:

     

Accounts payable

    $ 1,533     $ 1,523  

Accrued liabilities

      1,300       2,249  

Current portion of lease liability—operating

      541       518  

Current portion of lease liabilities—finance

      1,018       1,099  

Supplier financing

      —         117  
  

 

 

    

 

 

  

Total current liabilities

      4,392       5,506  

Non-current portion of lease liability—operating

      9,013       9,175  

Non-current portion of lease liabilities—finance

      1,011       1,200  

Payor liability

      6,149       6,132  
  

 

 

    

 

 

  

Total liabilities

      20,565       22,013  

Commitments and contingencies

     

Stockholders’ equity:

     

Preferred stock, $0.0001 par value, 5,000,000 shares authorized; 2,090 shares issued and outstanding at March 31, 2023 and December 31, 2022.

      —         —    

Common stock, $0.0001 par value, 150,000,000 shares authorized; 17,787,185 shares and 17,070,071 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively.

      2       2  

Additional paid-in capital

      308,008       307,296  

Accumulated deficit

      (305,582 )      (298,438 ) 
  

 

 

    

 

 

  

Total stockholders’ equity

      2,428       8,860  
  

 

 

    

 

 

  

Total liabilities and stockholders’ equity

    $ 22,993     $ 30,873  
  

 

 

    

 

 

  

 

3

Biocept, Inc.

Condensed Statements of Operations

(In thousands, except shares and per share data)

(Unaudited)

 

     For the Three Months Ended March 31,  
     2023     2022  

Net revenues

    $ 673     $ 19,945  

Costs and expenses:

     

Cost of revenues

      3,028       10,334  

Research and development expenses

      1,040       1,846  

General and administrative expenses

      2,988       6,256  

Sales and marketing expenses

      715       3,658  
  

 

 

    

 

 

  

Total costs and expenses

      7,771       22,094  
  

 

 

    

 

 

  

Loss from operations

      (7,098 )      (2,149 ) 

Other expense:

     

Interest expense, net

      (46 )      (61 ) 
  

 

 

    

 

 

  

Total other expense:

      (46 )      (61 ) 
  

 

 

    

 

 

  

Loss before income taxes

      (7,144 )      (2,210 ) 

Income tax expense

      —       —  
  

 

 

    

 

 

  

Net loss

      (7,144 )      (2,210 ) 
  

 

 

    

 

 

  

Net loss attributable to common stockholders

    $ (7,144 )    $ (2,210 ) 
  

 

 

    

 

 

  

Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders:

     

Basic

      17,620,668       16,849,964  
  

 

 

    

 

 

  

Diluted

      17,620,668       16,849,964  
  

 

 

    

 

 

  

Net loss per common share:

     

Basic

    $ (0.41 )    $ (0.13 ) 
  

 

 

    

 

 

  

Diluted

    $ (0.41 )    $ (0.13 ) 
  

 

 

    

 

 

  

# # #

 

4

EX-101.SCH 3 bioc-20230510.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 bioc-20230510_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Entity Registrant Name Entity Registrant Name Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 bioc-20230510_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g420466g91r76.jpg GRAPHIC begin 644 g420466g91r76.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Document and Entity Information
May 10, 2023
Cover [Abstract]  
Entity Registrant Name BIOCEPT INC
Amendment Flag false
Entity Central Index Key 0001044378
Document Type 8-K
Document Period End Date May 10, 2023
Entity Incorporation State Country Code DE
Entity File Number 001-36284
Entity Tax Identification Number 80-0943522
Entity Address, Address Line One 9955 Mesa Rim Road
Entity Address, City or Town San Diego
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92121
City Area Code (858)
Local Phone Number 320-8200
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol BIOC
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d420466d8k_htm.xml IDEA: XBRL DOCUMENT 0001044378 2023-05-10 2023-05-10 BIOCEPT INC false 0001044378 8-K 2023-05-10 DE 001-36284 80-0943522 9955 Mesa Rim Road San Diego CA 92121 (858) 320-8200 false false false false Common Stock, par value $0.0001 per share BIOC NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( -TPKU8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " #=,*]65I*B!.X K @ $0 &1O8U!R;W!S+V-O&ULS9+! M2L0P$(9?17)O)VWI"J&;B^))07!!\1:2V=U@TX9DI-VW-XV[740?P&-F_GSS M#4RGO=!CP.

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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - d420466d8k.htm 7 d420466d8k.htm bioc-20230510.xsd bioc-20230510_lab.xml bioc-20230510_pre.xml d420466dex991.htm http://xbrl.sec.gov/dei/2022 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d420466d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "d420466d8k.htm" ] }, "labelLink": { "local": [ "bioc-20230510_lab.xml" ] }, "presentationLink": { "local": [ "bioc-20230510_pre.xml" ] }, "schema": { "local": [ "bioc-20230510.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "bioc", "nsuri": "http://www.biocept.com/20230510", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d420466d8k.htm", "contextRef": "duration_2023-05-10_to_2023-05-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d420466d8k.htm", "contextRef": "duration_2023-05-10_to_2023-05-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.biocept.com//20230510/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001193125-23-144030-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-144030-xbrl.zip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�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end